InterAct Therapeutics

What InterAct Therapeutics does

InterAct Therapeutics is a privately held, pre-clinical biotechnology company developing gene therapies that target the tumor microenvironment at metastatic sites. The company is a spinout from UT Southwestern Medical Center, founded in 2025, and headquartered in Dallas, Texas with 1–10 employees. Its lead program, IAT-S2, is a first-in-class AAV8-based gene therapy designed to modulate the liver microenvironment to make it hostile to cancer cells, administered as a single intravenous dose and initially indicated for liver-dominant metastatic breast cancer—an addressable population of approximately 15,000 US patients annually, where median survival post-diagnosis is under three years and no approved therapies specifically target the tumor-liver microenvironment.

The company's discovery engine is its proprietary InterAct Print™ computational platform, which uses patented screening methods to identify gene candidates that disrupt the mechanism by which metastatic cancer cells kill neighboring liver cells to colonize new sites. The platform is positioned as expandable beyond breast cancer to metastases in multiple tumor types, and the company has explicitly stated an intent to "break the legacy gene therapy model" by targeting non-ultra-rare indications with lower dosing and below-traditional pricing.

InterAct is currently pre-revenue with no commercial product, and its revenue mechanics are entirely forward-looking. The company holds an exclusive licensing agreement with UT Southwestern Medical Center for development and commercialization of the platform and gene therapy pipeline, was selected into the Charles River Cell & Gene Therapy Incubator Program, and has completed a successful FDA INTERACT meeting for IAT-S2 with the goal of advancing toward an IND submission. Leadership includes co-founders Dan Hargrove (CEO, JD LLM) and Isaac Chan (CSO, MD/PhD), a Board of Directors member (Claire Aldridge, PhD), and a high-profile advisory board comprising former FDA Commissioner Steve Hahn, former NCI Director Kim Rathmell, MD Anderson's David Hong, and Duke Cancer Institute's Donald McDonnell.

Name

InterAct Therapeutics

Legal name

InterAct Therapeutics, Inc.

Website

https://interacttx.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

InterAct Therapeutics is a pre-clinical biotechnology spinout from UT Southwestern developing first-in-class AAV8-based gene therapies that target the tumor microenvironment at metastatic sites, with lead program IAT-S2 initially focused on breast cancer liver metastases.

Ownership category

akta.pro rank

Product category

Oncology Gene Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Gene therapy platforms
• Metastatic cancer treatment
• Oncology biotechnology
• AAV8 gene therapy
• Computational drug discovery

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Gene Therapy Development and Commercialization: As a pre-clinical stage biotechnology company, InterAct Therapeutics is focused on developing first-in-class gene therapies targeting metastatic disease. The company is working toward IND submission and clinical trials for IAT-S2. Revenue will likely come from therapeutic product commercialization upon regulatory approval.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

InterAct Therapeutics is a pre-clinical biotechnology company developing first-in-class gene therapies for metastatic cancer, with its lead program IAT-S2 being an AAV8-based gene therapy designed to treat breast cancer liver metastasis through a single intravenous administration that modulates the liver microenvironment. The company's pipeline is powered by its proprietary InterAct Print™ computational platform, which uses patented screening methods to identify gene targets that provide competitive advantage against metastatic cancer cells.

Product overview

InterAct Therapeutics is a biotechnology company developing first-in-class gene therapies targeting metastatic disease. The company's lead program IAT-S2 is an AAV8-based gene therapy specifically engineered for breast cancer liver metastases, supported by the proprietary InterAct Print™ computational platform. The platform enables identification and validation of therapeutic targets while the gene therapy pipeline addresses the tumor microenvironment in metastatic sites.

Differentiator

Problem solved

Functional benefit

Products and services

• IAT-S2 First-in-class AAV8-based gene therapy engineered to treat breast cancer liver metastasis by modulating the liver microenvironment to create an anti-tumorigenic environment. Delivered as a single intravenous dose, it is designed to prevent metastatic colonization and inhibit growth of established tumors in patients with liver-dominant metastatic breast cancer (estimated ~15,000 patients annually in the U.S.).
• InterAct Print™ Platform Proprietary computational platform that pinpoints cancer targets and powers anti-metastasis therapies. Uses patented screening methods to identify gene candidates that provide competitive advantage against metastatic cancer cells, with the goal of expanding beyond ultra-rare indications into multiple cancer metastasis types.

Quantifiable outcome

• 90% of cancer deaths are caused by metastasis
• +4 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• UT Southwestern Medical CentercoreStrategic or Co-development Partner · 24 March 2026Exclusive licensing agreement with UT Southwestern Medical Center to develop and commercialize a computational platform and gene therapy pipeline targeting cancer metastasis. The partnership leverages UT Southwestern's research capabilities and provides InterAct with access to the underlying technology and intellectual property.
• Charles River LaboratoriescoreStrategic or Co-development Partner · 11 December 2025Selected as participant in the second cohort of Charles River's Cell & Gene Therapy Incubator Program (CIP), launched in December 2024. The program supports early-stage biotech companies developing advanced therapies by providing access to expertise and infrastructure. Other participants include CureAge Therapeutics, Jaan Biotherapeutics, Kopra Bio, W.R. Grace & Co., and HTLab AG's BioWerkli.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Krystal Biotech: Commercial-stage gene therapy company with a proprietary platform for developing topical and inhaled gene therapies. Comparable platform-based gene therapy approach, though focused on a different delivery modality.
• Genprex: Clinical-stage gene therapy company developing novel gene therapies for cancer, with a focus on tumor suppressor genes and oncology indications. Highly comparable oncology-focused gene therapy development approach.
• uniQure: Gene therapy company pioneering AAV-based treatments for serious diseases, with a focus on liver-directed and CNS disorders. Directly comparable AAV platform approach and gene therapy development model.
• Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments for neurological diseases. Comparable AAV platform technology and pre-clinical/early-clinical stage gene therapy pipeline focus.
• Passage Bio: Clinical-stage genetic medicines company developing AAV-delivered therapies for rare monogenic CNS diseases. Directly comparable AAV gene therapy platform model and pre-clinical-to-clinical development stage.
• Solid Biosciences: Genetic medicines company developing AAV-based treatments with focus on precision gene therapy. Similar platform-based AAV approach to developing treatments for serious diseases.
• Regenxbio: Clinical-stage AAV gene therapy company developing treatments using its proprietary NAV Technology Platform. Highly comparable to InterAct's AAV8-based approach and pipeline-driven gene therapy model.
• Taysha Gene Therapies: Clinical-stage gene therapy company with a pipeline of AAV-based therapies initially focused on CNS diseases. Directly comparable pre-clinical/early-clinical AAV gene therapy development model.

Broad incumbents

• BioMarin Pharmaceutical: Established biopharmaceutical company with multiple approved gene therapies and a broad rare disease pipeline including AAV-based products. Broad incumbent in the gene therapy space with overlapping platform capabilities.
• Sarepta Therapeutics: Commercial-stage gene therapy leader with approved AAV-based treatments for Duchenne muscular dystrophy. Broad incumbent in gene therapy with established manufacturing, regulatory, and commercial infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/interact-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InterAct Therapeutics